Data from: Cost-minimization analysis Phesgo model

The main objective of this study is to determine whether the employment of
fixed-dose combination of pertuzumab and trastuzumab for subcutaneous
injection (or Phesgo) to treat metastatic HER2-positive breast cancer
patients would minimize costs compared to the traditional treatment of
separate intravenous doses of pertuzumab and trastuzumab in Peru. To
achieve this, we used EsSalud (the social security health insurance) data
and assessed it through a mixed strategy, which consisted of a
quantitative and a qualitative approach. The first one aimed to calculate
the direct (non-drug consumables, drugs, and healthcare professionals) and
indirect costs of both treatments to develop a comparison, whilst the
second aimed to validate information and internalize the procedure in an
EsSalud context. Overall, we found that the usage of Phesgo would be cost
saving in EsSalud’s context. Specifically, we found three main insights.
Firstly, the savings produced from switching from the traditional
intravenous treatment to the subcutaneous one would allow EsSalud to
afford full annual costs of 2 additional treatments, but without
increasing their budget. This would cover 7% of the gap of 29 patients who
do not have access to full treatment. Secondly, the result of a univariate
sensitivity analysis in this work indicates that the price of Phesgo would
have to increase by 16% so that both treatments cost the same. Thirdly, to
increase the number of patients, the intravenous treatment would have to
be totally replace by the Phesgo treatment, since the use of the latter
requires less personnel and infrastructure.